An observational study in Anemia, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by Charite University, Berlin, Germany · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Anemia with a site in Germany — 14 open to participants now, 27 under way, 14 of them phase 3. Anemia · Germany.
Among the 151 studies in Anemia with a site in Germany, this one is the 6th largest by planned enrollment of the 31 observational ones that give a count, is one of 10 that started in 2022, is one of 31 observational ones, reaches primary completion later than 12 of the 26 other live ones, and was the 129th registered.
1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.
Browse Anemia studies →14 of the 151 studies in Anemia with a site in Germany are open now. Recruiting first, the newest first:
Takeda · Sites in Germany, United States, Argentina and 28 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Germany
Ages 18+
Takeda · Sites in Germany, United States, Argentina and 25 more countries
Ages 18+
iOMEDICO AG · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in Germany, United States, Brazil and 3 more countries
Ages 2–18
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 30 · Phase 3 70 · Phase 4 8
First in 1996; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,700 is above the median of 270 across 368 observational studies indexed under Anemia.
Median enrollment 198 across the 120 interventional studies, 800 across the 31 observational. Of the 119 that completed or were terminated, 65 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 151 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 3 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Anemia with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
| NCT05146726Charite University, Berlin, GermanyPatient Blood Management Charité (PBM-Charité): Structured Detection, Differentiated Diagnostics and Therapy of Preoperative Anemia and Use of Machine Autotransfusion in Elective Interventions | 2027-02 |
| NCT07008261Goethe UniversityRobot-assisted Cystectomies With Regard to Blood Loss, Pain and Transfusions. | 2027-05-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 151 studies in Anemia with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of patient blood management is to reduce the risks of perioperative anemia- and transfusion-associated complications by limiting the use and the need for allogeneic blood transfusion.
Background of this multimodal, multidisciplinary concept are numerous studies that have shown an association between preoperative anemia and/or a perioperative transfusion and a worse treatment outcome concerning morbidity and mortality. Diagnosis and therapy of preoperative anemia and the use of machine autotransfusion are central components of this integrated supply concept based on the S3 guideline "Präoperative Anämie", which need to be incorporated into the clinical processes.
Therefore, all patients undergoing elective surgery with a probability of transfusion > 10% receive an anemia detection during their premedication visit. Patients who are insured with BARMER also get anemia diagnostic and therapy. Patients of other health insurances receive a recommendation to anemia diagnostics and therapy sent to surgical department. Based on an analysis of the primary and secondary endpoints of this prospective cohort study, the implementation of the mentioned guideline-compliant measures in everyday clinical practice and the effectiveness of an IV-PBM (Patient blood management) are to be examined. Thus, if necessary, other health insurances could join the patient blood management (PBM) IV concept. The aim is to provide evidence of an improved quality of treatment and the generalized application of PBM measures within the scope of the innovative PBM care form described.
Adult patients with preoperative anemia and an electivesurgical intervention with a probability of transfusion > 10%
Prospective:
Inclusion Criteria:
additionally for the use of MAT:
Exclusion Criteria:
Retrospective:
Inclusion Criteria:
-Data since September 2021-February 2024 of patients who are not insured with BARMER with elective (N5) interventions with a transfusion probability > 10% (indication list) with a preoperatively existing anemia
additionally for the use of MAT:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group I: BARMER insured patients with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion \> 10%. Central measures in this group are the IV contract for the creation of an organizational and financing structure for the guideline-compliant detection, diagnosis and treatment of preoperative anemia and the evaluation of the machine autotransfusion as part of the preoperative premedication visit in anesthesiology (implementation is the responsibility of the patient blood management (PBM) service).
Other: BARMER anemia treatment
Group II: Patients not insured with BARMER and with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion \> 10% and receive early anemia detection.
Other: NON-BARMER anemia treatment
BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.
Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability\> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
Number of patients
The amount of patients with differential diagnostics and causally appropriate therapy of a preoperative anemia of all patients with preoperative anemia before an elective surgical intervention with a probability of transfusion \> 10% at study completion date = third year after start date (implementation rate of therapy recommendation). Approximately 9600 patients will be enrolled in the study. The data is evaluated after 3 years.
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Number of patients
The amount of patients with differential diagnostics and causally appropriate therapy of a preoperative anemia of all patients with preoperative anemia before an elective surgical intervention with a probability of transfusion \> 10% after the first and second year after start date (implementation rate of therapy). The data of 2 is evaluated after 1 year and 2 years.
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Number of machine autotransfusion respectively autologous transfusion
Number of patients which received machine autotransfusion
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Rate of transfused patients
Number of patients which received transfusions
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
∆Hb before therapy of anemia and before surgical intervention
Difference between Hemoglobin before therapy of anemia and Hemoglobin before surgical intervention.
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Number of allogeneic transfusions
Number of red cell concentrates per patient
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Treatment period
Treatment period between begin of anemia therapy and surgical intervention
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Treatment dose of anemia therapeutics in relation to ∆Hemoglobin
Treatment dose of anemia therapeutics in relation to the difference between Hemoglobin before begin of anemia therapy and the Hemoglobin before surgical intervention
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Side effects 1
Side effects of anemia therapeutics
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Side effects 1
Type of side effects of anemia therapeutics
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Differences of secondary outcome measures
Differences of secondary outcome measures 2. - 10. mentioned above between long term and short term treatment (anemia therapy, long term treatment \>3 weeks preoperative, short term treatment 1 - 3 days preoperative).
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Anemia course
Change of Hemoglobin during hospital stay until hospital discharge
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Length of hospital stay
Length of stay at the hospital
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Length of intensive care unit stay
Length of stay at the intensive care unit
Time frame: The participants are followed up until the end of hospital stay, an expected average of 3 days
Rate and type of postoperative complications
Rate and type of Organ complications which are documented in the hospital records.
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Side effects 2
Type of side effects of machine autotransfusion
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Rate of side effects
Rate of side effects of machine autotransfusion
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Volumes of collected blood
Volumes of collected blood from Machine autotransfusion
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Retransfused blood
Retransfused blood from Machine autotransfusion
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Quality indicator 1
Quality indicators for machine autotransfusion as process time
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Quality indicator 2
Quality indicators for machine autotransfusion as operating time
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Quality indicator 3
Quality indicators for machine autotransfusion as number of washing processes
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Quality indicator 4
Quality indicators for machine autotransfusion as surgery department
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Quality indicator 5
Quality indicators for machine autotransfusion as patient population
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Rate of In-hospital mortality
Mortality is measured during hospital stay
Time frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.
Of 124 non-industry observational studies under Anemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 83. This study's planned 60 months is above that.
Counting every sponsor, half of 145 studies reached it within 30 months; a quarter within 11 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →